ニューロン酸化窒素合成酵素の選択的単離抑制剤である. 分子ダイナミクスシミュレーションからの結合モードの洞察
He Huang1, Haitao Ji, Huiying Li
1Department of Chemistry, Chemistry of Life Processes Institute, amd Center for Molecular Innovation and Drug Discovery, Northwestern University, 2145 Sheridan Road, Evanston, Illinois 60208-3113, USA.
Journal of the American Chemical Society
|June 27, 2012
まとめ
研究者らは,神経退行性疾患の治療のために,ニューロン酸化窒素合成酵素 (nNOS) の有力で選択的なモノケーション性阻害剤を設計した. これらの新しい化合物は,高い有効性を維持しながら,生物利用性を改善し,治療開発における重要な進歩を記しています.
科学分野:
- 薬用化学 薬用化学について
- 神経科学は神経科学である.
- コンピューティング・ケミストリー
背景:
- ニューロン酸化窒素合成酵素 (nNOS) の抑制は,神経変性疾患の治療の可能性を提供します.
- 以前のピロリジンベースのnNOS阻害剤は効能を示したが,複数の陽性電荷により生物利用性が低下した.
- 重要な課題は,阻害剤の効能や選択性を損なうことなく,陽性電荷を減らすことです.
研究 の 目的:
- nNOS阻害剤の薬理学的特性を,学際的なアプローチを用いて探求する.
- 新しい,強力で選択的な単離性nNOS阻害剤を設計し,生物利用性を向上させる.
主な方法:
- リガンド-タンパク質の相互作用を理解するために,分子ドッキング,結晶学,分子ダイナミクスシミュレーションを使用しました.
- 合成化学を用いて,新しいピロリジンベースのnNOS阻害剤を作成しました.
- 阻害剤の効能と選択性を評価するための酵素学試験を実施.
主要な成果:
- 水素結合,静電性,水害性相互作用,水橋などの主要な安定化要因を特定した.
- リンガンドのアロマティックヘッドまたはリンカーにヘテロアトームを組み込むことは,安定性を高め,基質結合ポケットをブロックすることを発見しました.
- 化合物10により膜透過性が向上したnNOS阻害剤をモノケチオン型ピロリジン基で開発した.
結論:
- 計算による洞察は,強力で選択的なモノケチオン性nNOS阻害剤の設計を成功裏に導きました.
- 開発された化合物は,潜在的な治療用途のためのnNOS阻害剤設計における重要な進歩を表しています.
- ヘテロ原子を組み込み,電荷状態を最適化する戦略は,薬剤の生物利用性を改善するための有望な経路を提供します.
関連する概念動画
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
01:16Protein-Drug Binding: Mechanism and Kinetics
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
01:22Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...